Osprey Pharmaceuticals USA is a clinical stage company focused on the development of novel protein therapeutics for the treatment of inflammatory and immune diseases.
The company is advancing a pipeline of proprietary fusion protein therapeutics known as Leukocyte Population Modulators (LPMs) that are designed to selectively target and neutralize chemokine-activated leukocytes underlying a variety of inflammatory and immune diseases.
The Companyâ€™s lead candidate, CCL2-LPM targeting the CCR2 chemokine receptor expressed by certain pathologically activated leukocytes is in a Phase Ib clinical trial for the treatment of IgA nephropathy.
Funding Rounds (4) - $25.89MUpdate
Current Team (1)Update
Board Members and Advisors (2)Update
|Oct 12, 2015||crunchbase.com - Sep 3, 2008: Osprey Pharmaceuticals USA - Funding Round - Series A|
|Oct 11, 2015||Fierce Biotech - Osprey Pharmaceuticals U.S.A., Inc. Completes $11 Million Initial Private Financing|
|Feb 4, 2014||SEC - SEC FORM D|
|Jun 18, 2009||Venture Beat - Osprey picks up $3.8M more for immune disease treatments|
|May 27, 2009||Xconomy - Osprey Pharmaceuticals Receives $3,800,000 Series A Round|
|Jan 30, 2007||PE HUB - PE HUB|
San Francisco, CA